کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8673689 | 1578846 | 2017 | 11 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Leukemic Transformation in Myeloproliferative Neoplasms
ترجمه فارسی عنوان
انتقال لوسمی در نئوپلاسم های میلوپرولیفراتیو
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DIPSSAMLBETIMPNPMFMDSRBCASCTPolycythemia veraEssential thrombocythemia - ترومبوسیتمی ضروریcomplete remission - رمی کاملWorld Health Organization - سازمان بهداشت جهانیmyelodysplastic syndrome - سندرم میلودیسپلاستیکFab - فابFrench-American-British - فرانسوی-آمریکایی-انگلیسیacute myeloid leukemia - لوسمی حاد میلوئیدی یا به اختصار AMLMyelofibrosis - میلوفیبروزprimary myelofibrosis - میلوفیفروس اولیهMyeloproliferative neoplasm - نئوپلاسم میلوپرولیفراتیوAllogeneic stem cell transplant - پیوند سلول های بنیادی آلوژنیکWHO - کهred blood cell - گلبول قرمز، اریتروسیت
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
Myeloproliferative neoplasms (MPNs) operationally include essential thrombocythemia, polycythemia vera, primary myelofibrosis (PMF), and prefibrotic PMF. All 4 MPN variants might progress into blast-phase disease (MPN-BP). For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3. The reported median survival figures for MPN-BP range from 1.5 to 2.5 months in patients treated with supportive care only, from 2.5 to 10 months in those receiving hypomethylating agents or low-dose chemotherapy, and from 3.9 to 9.4 months in those receiving induction chemotherapy. Three-year survival after allogeneic stem cell transplant was reported in 16% to 33% of patients. These observations validate the extremely poor prognosis associated with MPN-BP and the lack of effective drug therapy and highlight the need for urgent assessment of therapeutic values of investigational agents. In the meantime, affected patients might be best served with aggressive chemotherapy followed by allogeneic stem cell transplant after adequate blast clearance.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 92, Issue 7, July 2017, Pages 1118-1128
Journal: Mayo Clinic Proceedings - Volume 92, Issue 7, July 2017, Pages 1118-1128
نویسندگان
Meera MD, Ayalew MD,